FDA accepts supplemental application for Fortamet (metformin hydrochloride)
The FDA has accepted a supplemental application for Fortamet, a metformin hydrochloride product from Andrx Labs.
Company
Pharmaceutical intelligence for Andrx Labs with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.